Regorafenib: from clinical research to clinical practice

Regorafenib: from clinical research to clinical practice

Regorafenib is a new multiple tyrosine kinase inhibitor with anti-cancer and anti-angiogenic activity which application has been recently approved by the Russian Federation in patients with colon cancer and gastrointestinal tumors. The approval of application of regorafenib for the treatment of pati...

Full description

Bibliographic Details
Main Authors:	M Yu Fedyanin, A A Tryakin
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2017-09-01
Series:	Современная онкология
Subjects:	regorafenib colon cancer gastrointestinal tumor hepatocellular carcinoma
Online Access:	https://modernonco.orscience.ru/1815-1434/article/viewFile/27137/pdf

Similar Items

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
by: Po‐Yao Hsu, et al.
Published: (2022-01-01)

The role of regorafenib in the treatment of metastatic colorectal cancer
by: A A Tryakin
Published: (2016-06-01)

Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysis
by: Mikhail Yu Fedyanin, et al.
Published: (2019-09-01)

Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma
by: Jing-Yu Hou, et al.
Published: (2022-06-01)

Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types
by: Hofheinz RD, et al.
Published: (2021-07-01)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
by: Nicola Personeni, et al.
Published: (2018-06-01)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
by: Yuan-Hung Kuo, et al.
Published: (2021-05-01)

Regorafenib-loaded poly (lactide-co-glycolide) microspheres designed to improve transarterial chemoembolization therapy for hepatocellular carcinoma
by: Xiang Li, et al.
Published: (2020-11-01)

Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
by: Yue Han, et al.
Published: (2021-10-01)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
by: Wan Wang, et al.
Published: (2019-10-01)

A novel strategy of regorafenib in combination with TAS102 against hepatocellular carcinoma
by: ZHANG Jun , DONG Yuhua , YANG Ye , ZHANG Mengqi , HE Chang
Published: (2021-04-01)

Efficacy and Prognostic Factors of Regorafenib in the Treatment of BCLC Stage C Hepatocellular Carcinoma After Failure of the First-Line Therapy
by: Xu B, et al.
Published: (2023-02-01)

The use of regorafenib in colorectal cancer
by: Marina I Sekacheva, et al.
Published: (2019-06-01)

Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report
by: Yanzhi Wan, et al.
Published: (2023-10-01)

Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression
by: Jianliang Xu, et al.
Published: (2019-07-01)

Regorafenib application in patients with metastatic colorectal cancer in actual clinical practice
by: M I Sekacheva, et al.
Published: (2016-09-01)

Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib
by: Piero Colombatto, et al.
Published: (2021-04-01)

Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center
by: Qingwei Zhu, et al.
Published: (2023-02-01)

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab
by: Andrea S. Fung, et al.
Published: (2020-07-01)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
by: Anant Ramaswamy, et al.
Published: (2019-01-01)

FOXM1-CD44 Signaling Is Critical for the Acquisition of Regorafenib Resistance in Human Liver Cancer Cells
by: Kenly Wuputra, et al.
Published: (2022-07-01)

PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
by: Yongkang Xu, et al.
Published: (2022-09-01)

Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines
by: Kei Takuma, et al.
Published: (2022-01-01)

Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance
by: Zou X, et al.
Published: (2023-02-01)

Changes in Wnt and TGF-β Signaling Mediate the Development of Regorafenib Resistance in Hepatocellular Carcinoma Cell Line HuH7
by: Mustafa Karabicici, et al.
Published: (2021-08-01)

Induction of Apoptosis, Inhibition of MCL-1, and VEGF-A Expression Are Associated with the Anti-Cancer Efficacy of Magnolol Combined with Regorafenib in Hepatocellular Carcinoma
by: Cheng-Hsien Chen, et al.
Published: (2021-04-01)

Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer
by: O I Kit, et al.
Published: (2017-06-01)

Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis
by: Huilin Xu, et al.
Published: (2023-10-01)

On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma
by: Hung-Wei Wang, et al.
Published: (2021-07-01)

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
by: Elif Şenocak Taşçı, et al.
Published: (2024-01-01)

Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma
by: Weiwei Shi, et al.
Published: (2020-06-01)

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
by: Kristina Breitenecker, et al.
Published: (2023-09-01)

Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
by: Xu Y, et al.
Published: (2023-10-01)

Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment
by: Hiromichi Nakajima, et al.
Published: (2021-06-01)

The role of a multidisciplinary approach in the treatment of hepatocellular carcinoma
by: Oleg I. Kit, et al.
Published: (2020-05-01)

Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma
by: I-Cheng Lee, et al.
Published: (2022-04-01)

Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer
by: Selina K. Wong, et al.
Published: (2019-10-01)

Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
by: Kun-Huei Yeh, et al.
Published: (2021-11-01)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
by: Cheol-Hyung Lee, et al.
Published: (2020-07-01)

Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma
by: Li J, et al.
Published: (2023-04-01)